A substantial advancement in diabetes care is emerging with the introduction of tirzepatide at a dosage of 45mg. This updated formulation builds upon the existing success of tirzepatide, a dual GIP and GLP-1 agonist, https://albertdgxh507708.wikistatement.com/5606799/revolutionary_development_tirzepatide_45mg_for_blood_sugar_control